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Case Report
The Role of the Pharmacist in the Treatment of
Infantile Botulism
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Infantile botulism is a potentially devastating disease caused by ingestion of Clostridium botulinum spores through food products or dust particles. The toxin produced by the
spores can lead to descending paralysis requiring hospitalization for supportive care which
sometimes includes mechanical ventilation. Human Botulism Immune Globulin-Intravenous
(BIG-IV or BabyBIG) from the Infant Botulism Treatment and Prevention Program (IBTPP)
has been shown to greatly improve outcomes. A previously healthy 5-month-old infant
was admitted to her regional hospital for poor feeding and lethargy. When the weakness
progressed and she had trouble with protecting her airway, she was intubated and transferred to our institution. The primary diagnosis was infantile botulism and the decision was
made to treat with BabyBIG. The pharmacy department was able to assist with obtaining
BabyBIG, ensuring proper preparation, and coordinating the team for swift administration.
In the days following the BabyBIG administration, the patient slowly started to recover her
respiratory function and muscle tone. On day five of admission the patient was extubated.
After transfer to the general pediatric floor the patient was given a transpyloric feeding
tube and worked with gastrointestinal and nutrition services to improve oral feeding. She
was discharged on day seventeen with plans to continue working with therapy and nutrition. BIG-IV can have a major impact in the recovery of infantile botulism. Pharmacists are
in an optimal position to assist with coordinating the multidisciplinary team regarding its
procurement, preparation, and administration.
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Introduction

Infantile botulism occurs when an infant less
than one year old ingests and becomes colonized with Clostridium botulinum spores in
their gastrointestinal tract. It is the most common type of botulism infection with around
100 new cases reported each year in the United
States. Although mortality has improved vastly
in recent years from 90% to less than 15%,
around half of patients with infantile botulism
will require invasive mechanical ventilation, and
recovery often takes several months to a year.
Common pathways of ingesting Clostridium
botulinum spores include raw honey, corn syrup,
improperly sterilized canned foods and dust.
Parents are often educated to avoid exposing
their infants to honey and corn syrup in the

first year of life since these two substances
alone account for 20% of new infantile botulism cases. In addition to processed sugars,
living in a rural area or being exposed to dust
from construction sites has contributed to
an increasing proportion of infantile botulism
cases in recent years. Regional differences have
been noted with more than 50% of new cases
in the past 30 years being reported in infants
living in California. This increase in incidents is
attributed to a higher prevalence of Clostridium botulinum spores in California’s soil compared to other states.1
Infants are more at risk for spore germination
and botulism infection than other age groups
due to their immature immune systems,
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underdeveloped gastric bacterial flora and
higher gastric pH compared to older children
or adults. The Clostridium botulinum spore is
a gram-positive, anaerobic, toxin-producing
bacillus. This potent toxin inhibits the release
of acetylcholine at neuromuscular junctions
and leads to a descending flaccid paralysis that
is commonly referred to as “floppy baby syndrome.” Symptoms include poor feeding, lethargy, constipation, ptosis in the face and eyes,
excessive drooling and shallow breathing.1
The differential diagnosis of infantile botulism
often includes sepsis, electrolyte imbalances,
metabolic disorders, Leigh disease, myasthenia gravis and Guillain-Barre syndrome.1 While
a proper disease workup is being completed,
supportive care and antimicrobials should be
initiated as indicated. Infants may experience
descending paralysis that impacts their respiratory muscles prompting respiratory support.1 It
is imperative that as soon as infantile botulism
is suspected, a diagnostic stool sample is sent
and treatment is started, as quick intervention
is critical in achieving optimal outcomes.
Human Botulism Immune Globulin-Intravenous (BIG-IV), otherwise known as “BabyBIG”,
is a human derived botulism antitoxin that
has revolutionized the treatment of infantile
botulism.2 A randomized clinical trial completed
in California by Arnon and colleagues compared
infants with botulism who received either
intravenous immunoglobulin (IVIG) (n=63) or
BabyBIG (n=59).2 In the BabyBIG group, mean
length of hospital stay was 2.6 weeks compared to 5.7 weeks in the IVIG group (p<0.001).
Hospital charges were used as a marker of
illness severity and were $74,800 in the BabyBIG group and $163,400 in the IVIG group. In
the subsequent nationwide, open-label study,
investigators found that administration of
BabyBIG saved $34.2 million through avoided
hospital costs. With the noted improvements
in hospital length of stay and overall medical
costs, BabyBIG is now considered first line
therapy for the treatment of infantile botulism.
The pharmacy team should be notified as soon
as the differential diagnosis includes infantile
botulism since BabyBIG can only be obtained
through the Infant Botulism Treatment and
Prevention Program (IBTPP) located in California. This process can be complex and require
input from several stakeholders.3 Pharmacists
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are in an optimal role to assist the team with
ordering, preparing and administering BabyBIG
in a timely manner.

Case Presentation

A previously healthy five-month-old female
presented to a regional emergency department with a three-day history of decreased
oral intake, somnolence/lethargy, worsening
head and neck control and constipation. She
was eventually admitted for dehydration and
lab abnormalities. Throughout the admission,
the patient had frequent low blood sugars that
were corrected with dextrose 10% bolus doses.
Due to increased somnolence and inability to
handle oral secretions, the patient was intubated and transferred to our pediatric intensive
care unit (PICU), which serves as a tertiary
referral center for Colorado and surrounding
states. Upon arrival at our facility, the initial
differential diagnosis included drug ingestion,
hypoglycemia, seizures and meningitis. The initial workup included laboratory values, lumbar
puncture, cerebrospinal fluid, blood and urine
cultures and x-rays. The patient was empirically
started on vancomycin (dosed to a goal trough
of 15–20 mcg/mL) and ceftriaxone 100mg/kg/
day while the workup was in progress. Infection
was ruled out based on culture results and lab
markers not indicating infection. Urine toxicology ruled out ingestion. A comprehensive list of
admission lab and test results can be found in
Tables 1 and 2.
On day two of admission, the presumed diagnosis was infantile botulism. The decision was
then made to treat the patient with BabyBIG.
Pediatric infectious disease and neurology
services were consulted and in agreement with
this decision. The patient was constipated and
needed two enemas to produce a stool sample that could be sent for a botulism assay. To
order BabyBIG, the attending physician and
the PICU pharmacist completed the necessary
paperwork and arranged for BabyBIG to be
delivered to the hospital. Given the COVID-19
pandemic, there were less flights from Los Angeles to Denver. Therefore, the medication did
not arrive at the facility until the next morning.
A provider with the IBTPP was in communication with the health care team until the medication arrived at the facility. On day three of
admission, BabyBIG 365 mg (50mg/kg) was
administered with intravenous acetaminophen

Huntsman and Schauble. (2021) 2:4. https://doi.org/10.36518/2689-0216.1293

Table 1. Admission Lab Results
Lab

Result [Range]

Complete Blood Count
White Blood Cell Count

6.25 cells×109/L [7.7–13.7]

Red Blood Cell Count

4.40 cells×106/L [3.3–4.7]

Hemoglobin

11.3 g/dL [9.5–13.3]

Hematocrit

35.4% [27–38.5]

Platelet Count

412 cells×109/L [150–500]

Basic Metabolic Panel
Sodium

140 mmol/L [136–145]

Potassium

4.1 mmol/L [3.4–4.5]

Chloride

111 mmol/L [98–107]

Carbon Dioxide
Anion Gap
Random Glucose
Blood Urea Nitrogen
Serum Creatinine

19 mmol/L [17–29]
10 mmol/L
103 mg/dL [60–100]
14 mg/dL [1–14]
0.25 mg/dL [0.1–0.4]

Total Protein

5.4 g/dL [5.7–8.2]

Albumin

4.2 g/dL [3.8–5.4]

Calcium

9.3 mg/dL [8.0–11.4]

Total Bilirubin

0.2 mg/dL [0.3–1.2]

Aspartate Transaminase

34 units/L [ 13–40]

Alanine Aminotransferase

26 units/L [10–49]

Alkaline Phosphatase
Quantitative C Reactive Protein

191 units/L [124–341]
< 0.4 mg/dL [<1.0]

Blood Gas
pH

7.22 [7.36–7.40]

pCO2

46 mmHg [35–45]

pO2

60 mmHg [55–70]

Bicarbonate

19 mmol/L [20–22]

Oxygen Saturation
Base deficit
Lactate

85% [90–96]
-9 mmol/L [-4.0–4.0]
1.1 mmol/L [0.4–2.0]

Serology
Herpes Simplex Virus Type 1

Not Detected

Herpes Simplex Virus Type 2

Not Detected
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Table 2. Admission Culture and Imaging Results
Test

Result [Range]

Cerebrospinal Fluid
Cerebrospinal Fluid Color
Red Blood Cell Count

Clear/Colorless [Clear]
4 cells/mcL [0–10]

Neutrophil Cell Percent
Nucleated Cell Count

0% [0–5]
0 cells/mcL [0–5]

Lymphocyte Cell Percent

55% [40–80]

Monocytes/Macrophages Cell Percent

45% [15–45]

Cultures
Cerebrospinal Fluid

No growth

Blood

No growth

Urine

One colony at < 10,000 organisms/mL

Respiratory Viral Panel

No growth

MRSA* Nasal Swab

Negative

Imaging
Chest X-ray
Abdomen KUB† X-ray

Mild bronchitis or viral lower respiratory tract
infection
Stool limit at upper limit of normal

*MRSA: Methicillin-resistant staphylococcus aureus
†KUB: Kidneys, ureters, bladder

15mg/kg and intravenous diphenhydramine
1 mg/kg as premedications. The patient did not
experience any infusion reactions.
After administering BabyBIG, the patient had
notable improvement in muscle tone and
strength over the next few days. She was extubated and transferred from the PICU to the
general pediatric floor on day five of admission.
With work from speech, respiratory, physical and occupational therapies, the patient’s
neurologic and respiratory functions continued
to improve. Enteral feeding was reintroduced
slowly, and the gastroenterology service was
consulted to assist with the progression from
transpyloric tube feeds to oral feeds. On day
14 of admission, the stool sample resulted as
positive for botulinum toxin type A. On day 17
of admission, the patient was discharged with
a nasogastric tube and follow-up appointments with an outpatient dietician as well as
with speech, physical and occupational therapists. In total, the patient spent six days in the
PICU, five days on a ventilator and 18 days in
the hospital.
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Discussion

The decision to administer BabyBIG can be
paramount in an infant’s recovery from infantile botulism. Quick coordination of the health
care team is needed to order the medication,
prepare for its arrival and ensure all necessary
employees are educated on its preparation and
administration. Pharmacists are vital to this
process.
Ordering BabyBIG will involve the attending
physician, covering pharmacist and pharmacy
administration. The attending physician will
begin the process by contacting the IBTPP’s
on-call physician and providing necessary information about the case. Once the on-call physician determines that the patient is eligible for
BabyBIG, the attending physician and pharmacist can complete the invoice and purchase
agreement found on the IBTPP website to
order the medication.3 This seven page document requires input from a pharmacy director/
purchaser for completion as the medication
costs $57,300, and payment must be secured
before the medication can be shipped. Once all
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documentation and payment is received by the
IBTPP, the medication will be shipped from Los
Angeles to the ordering facility with all transport arranged by the IBTPP. The on-call physician with the IBTPP will likely remain in contact
with the facility pharmacist to confirm receipt
of the necessary ordering materials and delivery of BabyBIG. They may also remain in contact with the attending physician for updates
on the clinical status of the patient.
Given the high expense of this medication and
complex procedure for obtaining it, any error in
preparation or administration can be devastating. It is important that any health care worker
who comes in contact with the medication in
any capacity is educated on how to perform
their role properly. The pharmacy team must
be notified immediately upon the medication’s
arrival so that storage requirements can be
met. The pharmacist and technicians who will
be involved in reconstitution and preparation
of the BabyBIG dose must be educated on
preparation instructions so the medication can
be prepared appropriately on the first attempt
since no extra drug will be provided to the
facility. BabyBIG must begin infusing within
two hours of preparation and must be done
infusing within four.4 The typical infusion time
for BabyBIG is one hour.4 This strict timeline
emphasizes the importance of effective communication between the nursing staff and the
pharmacy prior to BabyBIG’s arrival as well as
when both parties are ready to move forward
with its preparation and administration.
The nursing staff must be aware of the administration requirements prior to BabyBIG’s
arrival so any necessary adjustments can be
made with staffing, resources, etc. An infusion
pump is necessary for BabyBIG administration,
which should occur through a dedicated IV line
with no other medications or fluids running.4 If
this pump or IV access is not already available,
it must be obtained prior to BabyBIG’s arrival
at the facility. Educating the nursing staff on
the importance, expense and time sensitivity of
this medication is important in reinforcing the
urgency of these tasks.
BabyBIG is a form of immunoglobulin. Therefore administration, monitoring and infusion
reactions are similar to that of IVIG. The infusion rate must start slower, at 25 mg/kg/hr,

and, if no untoward reactions are seen after
15 minutes, the rate can be increased to 50
mg/kg/hr.4 Common premedications such as
analgesics and antihistamines can assist with
tolerating the infusion. Appropriate monitoring
for events such as infusion reactions, anaphylaxis, renal dysfunction, hemolytic anemia,
thrombotic events, hyperproteinemia, hyponatremia, blood hyperviscosity, aseptic meningitis
syndrome and transfusion-related acute lung
injury (TRALI) should occur during and after
BabyBIG infusion when appropriate.4 After the
infusion, the recipient will have six months of
botulinum toxin neutralization and protection
from the two most common types of botulinum toxin—types A and B.2 As seen in this patient and in the trial listed above, full recovery
is possible but can take time.

Conclusion

In this case, quick identification of infantile
botulism, through typical presenting symptoms
and noted exposure to common risk factors,
allowed our patient to receive a dose of BabyBIG swiftly, which led to a prompt resolution
of her infantile botulism, ultimately saving her
life. While the patient’s mother had ingested
home-canned goods and breastfed the patient,
it is not believed that Clostridium botulinum
spores pass through breastmilk. Therefore, the
final causative theory is the family’s residence
in a rural area or the father’s work in construction. As medication experts, pharmacists are
optimally positioned to assist members of
the multidisciplinary team with all aspects of
BabyBIG education and use so that its impact
is maximized.
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